1. Home
  2. PINE vs CABA Comparison

PINE vs CABA Comparison

Compare PINE & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpine Income Property Trust Inc.

PINE

Alpine Income Property Trust Inc.

N/A

Current Price

$16.63

Market Cap

317.1M

Sector

Real Estate

ML Signal

N/A

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

N/A

Current Price

$1.29

Market Cap

339.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PINE
CABA
Founded
2019
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
317.1M
339.1M
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
PINE
CABA
Price
$16.63
$1.29
Analyst Decision
Buy
Buy
Analyst Count
11
10
Target Price
★ $19.70
$11.75
AVG Volume (30 Days)
163.0K
★ 4.6M
Earning Date
10-22-2026
11-05-2026
Dividend Yield
★ 7.67%
N/A
EPS Growth
N/A
★ 10.26
EPS
★ 0.42
N/A
Revenue
★ $60,532,000.00
N/A
Revenue This Year
$31.91
N/A
Revenue Next Year
$10.40
N/A
P/E Ratio
$39.79
★ N/A
Revenue Growth
★ 15.90
N/A
52 Week Low
$15.81
$1.18
52 Week High
$21.99
$4.23

Technical Indicators

Market Signals
Indicator
PINE
CABA
Relative Strength Index (RSI) 43.83 35.07
Support Level $16.62 $1.18
Resistance Level $17.10 $1.63
Average True Range (ATR) 0.44 0.13
MACD 0.06 0.03
Stochastic Oscillator 55.10 24.44

Price Performance

Historical Comparison
PINE
CABA

About PINE Alpine Income Property Trust Inc.

Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Share on Social Networks: